Track topics on Twitter Track topics that are important to you
Rare diseases therapies start-up Rallybio LLC raised $37mm in its Series A financing co-led by 5AM Ventures, Canaan Partners, and New Leaf Venture Partners, which were joined by Connecticut Innovation...
A Westport venture capital fund is among the investors in Rallybio, a Farmington startup that announced on Wednesday initial funding totaling $37 million under former research heads of Alexion Pharmac...
With $37 million in its pocket a new player has emerged to develop treatments for rare diseases.
A trio of former Alexion executives launched Rallybio with $37 million to build a pipeline of rare disease candidates.
Although sales of the closely-watched atopic dermatitis drug Dupixent disappointed in the first quarter, the French major sees the fall...
Rallybio was established to identify and accelerate the development of transformative breakthrough therapies for patients with severe and rare disorders. The founders of the compa...
We have published hundreds of Rallybio, LLC news stories on BioPortfolio along with dozens of Rallybio, LLC Clinical Trials and PubMed Articles about Rallybio, LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Rallybio, LLC Companies in our database. You can also find out about relevant Rallybio, LLC Drugs and Medications on this site too.
Bioscience - any of the sciences that deal with living organisms. The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...